Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan
| Autor: | Gerry Oster, Derek Weycker, A Keskinaslan, Drew Griffin Levy, Alex Kartashov, John Edelsberg |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Databases Factual Drug Resistance Tetrazoles Blood Pressure Angiotensin II Type 1 Receptor Blockers Cohort Studies Young Adult Internal medicine Internal Medicine medicine Humans cardiovascular diseases Amlodipine Antihypertensive Agents Aged Retrospective Studies business.industry Retrospective cohort study Valine General Medicine Middle Aged Calcium Channel Blockers Add on therapy Endocrinology Blood pressure Treatment Outcome Valsartan Hypertension Cardiology Population study Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business circulatory and respiratory physiology medicine.drug |
| Zdroj: | Blood pressure. Supplement. 2 |
| ISSN: | 0803-8023 |
| Popis: | To describe the real-world effectiveness of amlodipine add-on therapy for hypertensive patients receiving valsartan.Retrospective cohort study based on USA electronic medical records. The study population included hypertensive patients who, between January 1998 and December 2005, were receiving valsartan and subsequently initiated add-on therapy with amlodipine. Change in systolic blood pressure (SBP)/diastolic blood pressure (DBP), and attainment of goal SBP/DBP (i.e.140/90 mmHg), were examined based on last available reading prior to day 180 following initiation of amlodipine.Mean (+/- SD) baseline SBP/DBP of study subjects (n=155) was 152.5 (+/- 21.1)/84.0 (+/- 13.5) mmHg. Add-on therapy with amlodipine reduced SBP by 13.3 mmHg (95% CI 9.4-17.1) and DBP by 6.1 mmHg (95% CI 4.2-8.1). Among patients with baseline SBP/DBPor = 160/100 mmHg (n=69), corresponding reductions were 28.8 mmHg (95% CI 23.4-34.2) and 11.4 mmHg (95% CI 8.4-14.3). Goal SBP/DBP was achieved by 46% (95% CI 37.7-55.6) of subjects; rates of goal attainment were similar for patients with and without diabetes or chronic kidney disease, and those agedor = 65 years versus younger.Adding amlodipine to valsartan for treatment of hypertension results in clinically meaningful reductions in blood pressure, on an overall basis and in high-risk subgroups who may benefit the most from blood pressure control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|